The company has not filed an annual or quarterly report since its Q3 FY2022 10-Q, filed Nov 10, 2022. Its latest SEC filing is a 15-12G from Mar 20, 2023.
10-Q for Q3 FY2022, filed Nov 10, 2022
The sections below describe the company as of the FY2021 annual report.
Develops antibody-based cancer drug candidates and licenses its antibody platform to pharmaceutical and biotechnology companies developing medicines in oncology, immunology and central nervous system conditions.
10-K for FY2021, filed Mar 15, 2022
Pharmaceutical and biotechnology partners pay upfront for licenses and for research work as it is performed; other payments can come when options are exercised or development milestones are reached, and royalties may arrive when partner products sell.
10-K for FY2021, filed Mar 15, 2022The Company’s revenues are generated primarily through license and collaboration agreements with pharmaceutical and biotechnology…View ↗
The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license…View ↗
Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the…View ↗
Milestone payments: The Company’s collaboration agreements may include development and regulatory milestones. The Company evaluates whether…View ↗
Research and Development Services: The promises under the Company’s collaboration agreements may include research and development services…View ↗
Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is…View ↗
$21.2M
10-K for FY2021, filed Mar 15, 2022
$21.2M ↗
Pharmaceutical and biotechnology companies work with F-star through license and collaboration agreements to develop drug candidates using its antibody platform.
10-K for FY2021, filed Mar 15, 2022
No. It lost $31.3M in FY2021.
10-K for FY2021, filed Mar 15, 2022
−$30.7MView ↗
10-K for FY2021, filed Mar 15, 2022
−$31.3MView ↗
10-K for FY2021, filed Mar 15, 2022
−$27.9MView ↗
10-Q for Q3 FY2022, filed Nov 10, 2022
−$18.4MView ↗
8-K, filed Mar 9, 2023
As described in the Introductory Note, on December 29, 2022, Purchaser irrevocably accepted for payment all Company Shares validly tendered…View ↗
8-K, filed Mar 7, 2023
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass. – March 7, 2023 (Globe Newswire) F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the…View ↗
8-K, filed Dec 29, 2022
Effective at December 29, 2022 at 12:05 a.m. Eastern Time, the Committee on Foreign Investment in the United States (“CFIUS”) issued an…View ↗
A shift to antibody-based cancer drugs
The older report centered on small-molecule nucleotide drugs for viral and inflammatory diseases, especially chronic hepatitis B; the latest centers on antibody-based cancer immunotherapies and a bispecific antibody platform, with antibody candidates in clinical development.
10-K for FY2018, filed Mar 11, 2019 10-K for FY2021, filed Mar 15, 2022We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics for the…View ↗
More partner platform licensing
The older report described compounds for which F-star retained exclusive global commercial rights; the latest also describes licensing its platform and partner-developed programs alongside its own product candidates.
10-K for FY2018, filed Mar 11, 2019 10-K for FY2021, filed Mar 15, 2022The following table summarizes the status of our development pipeline. We retain exclusive global commercial rights to all of our compounds.View ↗
We are a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of…View ↗
We currently have collaborative partnerships with Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany, Denali Therapeutics…View ↗
The Company’s revenues are generated primarily through license and collaboration agreements with pharmaceutical and biotechnology…View ↗
Competes with AstraZeneca, BMS, EMD Serono, Genentech, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, Genmab, Inhibrx, MacroGenics, Merus, Pieris Pharmaceuticals, Hoffmann-LaRoche, Shattuck Labs, Xencor, Epimab, Innovent, and Regeneron
10-K for FY2021, filed Mar 15, 2022We compete in the segments of the biotechnology, pharmaceutical and other related markets that develop immuno-oncology therapies. There are…View ↗
Loading...
